# Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS

> **NCT04745299** · PHASE3 · COMPLETED · sponsor: **Corestemchemon, Inc.** · enrollment: 123 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **BIOLOGICAL:** Lenzumestrocel
- **DRUG:** Riluzole
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT04745299
- **Lead sponsor:** Corestemchemon, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-24
- **Primary completion:** 2024-10-03
- **Final completion:** 2024-11-13
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04745299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04745299, "Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04745299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*